Centocor Collaboration
- Date:
- 1989-2008
- Reference:
- SA/KET/A/2
- Part of:
- The Kennedy Trust for Rheumatology Research
- Archives and manuscripts
Collection contents
About this work
Description
Records relating to the research collaboration between The Charing Cross Sunley Research Centre, The Kennedy Institute and Centocor Biotech. The research collaboration aimed to utilise the Centocor owned chimeric anti-TNF antibody (cA2) for clinical trials in rheumatoid arthritis.
Includes correspondence between Marc Feldmann and Ravinder Maini and Centocor staff, research and material transfer agreements, meeting minutes and reports, financial papers relating to the collaboration, data, and manuscripts. The subsection also contains more general papers relating to Centocor’s activities as a biotechnology company.
See references SA/KET/A/1 for clinical studies sponsored by Centocor, SA/KET/A/4/3 for patents tied to the research and licensing agreement with Centocor and SA/KET/C/1/3 for papers relating to Marc Feldmann's consultancy work with Centocor.